Literature DB >> 12555663

Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens.

Lydie Trautmann1, Nathalie Labarrière, Francine Jotereau, Vaios Karanikas, Nadine Gervois, Thierry Connerotte, Pierre Coulie, Marc Bonneville.   

Abstract

We have studied the TCR features and functional responses of three sets of human cytolytic T cell (CTL) clones, recognizing antigenic peptides presented by HLA-A2 and derived from the Epstein-Barr virus proteins BMLF1 and BRLF1 and from the melanoma protein Melan-A/MART-1. Within each set, a majority of clones used a recurrent V alpha region, even though they expressed highly diverse TCR beta chains and V(D)J junctional sequences. Functional assays and peptide/MHC multimer binding studies indicated that this restricted V alpha usage was not associated with the affinity/avidity of the CTL clones. The V alpha dominance, which may be a frequent feature of antigen-specific T cells, likely reflects a restricted geometry of TCR/peptide/MHC complexes, primarily determined by V alpha CDR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555663     DOI: 10.1002/1521-4141(200211)32:11<3181::AID-IMMU3181>3.0.CO;2-2

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

1.  Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.

Authors:  David H Aggen; Adam S Chervin; Francis K Insaidoo; Kurt H Piepenbrink; Brian M Baker; David M Kranz
Journal:  Protein Eng Des Sel       Date:  2010-12-14       Impact factor: 1.650

2.  Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Authors:  David K Cole; Fang Yuan; Pierre J Rizkallah; John J Miles; Emma Gostick; David A Price; George F Gao; Bent K Jakobsen; Andrew K Sewell
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

3.  Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.

Authors:  Laurent Derré; Marc Bruyninx; Petra Baumgaertner; Mathias Ferber; Daphné Schmid; Antoine Leimgruber; Vincent Zoete; Pedro Romero; Olivier Michielin; Daniel E Speiser; Nathalie Rufer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

4.  Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis.

Authors:  Shalyn C Clute; Levi B Watkin; Markus Cornberg; Yuri N Naumov; John L Sullivan; Katherine Luzuriaga; Raymond M Welsh; Liisa K Selin
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

5.  Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.

Authors:  Toshiki Ochi; Munehide Nakatsugawa; Kenji Chamoto; Shinya Tanaka; Yuki Yamashita; Tingxi Guo; Hiroshi Fujiwara; Masaki Yasukawa; Marcus O Butler; Naoto Hirano
Journal:  Cancer Immunol Res       Date:  2015-05-05       Impact factor: 11.151

6.  CD28neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs.

Authors:  Hisayoshi Hashimoto; Marco Sterk; Karin Schilbach
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

7.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

8.  Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.

Authors:  Laura A Johnson; Bianca Heemskerk; Daniel J Powell; Cyrille J Cohen; Richard A Morgan; Mark E Dudley; Paul F Robbins; Steven A Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

9.  In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.

Authors:  Cari F Kessing; Christopher C Nixon; Chuan Li; Perry Tsai; Hiroshi Takata; Guillaume Mousseau; Phong T Ho; Jenna B Honeycutt; Mohammad Fallahi; Lydie Trautmann; J Victor Garcia; Susana T Valente
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

Review 10.  Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.

Authors:  Emanuela M Iancu; Petra Baumgaertner; Sébastien Wieckowski; Daniel E Speiser; Nathalie Rufer
Journal:  J Biomed Biotechnol       Date:  2010-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.